Table 3.
Outcomes of patients experiencing IHCA separated into severe and no severe AKI cohorts
| Severe AKI |
||||
|---|---|---|---|---|
| Overall (N = 313) | Yes (N = 207) | No (N = 106) | P-value | |
| Peak serum creatinine: Median (Q1, Q3) | 0.8 (0.5, 1.5) | 1.2 (0.8, 2.0) | 0.4 (0.3, 0.6) | <.0011 |
| Peak BUN: Median (Q1, Q3) | 27 (17, 45) | 36 (22, 49) | 18 (12, 25) | <.0011 |
| Peak ALT (Day 0–5) (U/L): Median (Q1, Q3) | 95 (42, 300) | 134 (53, 438) | 67 (36, 136) | <.0011 |
| UOP < 0.5 cc/kg/hr in a 24 hour period (Days 1–3) | 46/279 (16%) | 43/184 (23%) | 3/95 (3%) | <.0012 |
| Average UOP (cc/kg/hr) (Days 1–3): Median (Q1, Q3) | 3.5 (1.8, 5.2) | 3.3 (1.2, 5.1) | 4.1 (2.5, 5.2) | 0.0331 |
| Lowest UOP in a 24 hour period (cc/kg/hr) (Days 1–3): Median (Q1, Q3) | 1.9 (0.8, 3.6) | 1.6 (0.6, 3.7) | 2.2 (1.3, 3.6) | 0.0051 |
| Hospital Mortality | 144/312 (46%) | 107/206 (52%) | 37/106 (35%) | 0.0062 |
| 1 year Mortality | 161/311 (52%) | 119/206 (58%) | 42/105 (40%) | 0.0042 |
| 1 year survival with VABS-II score ≥703 | 92/246 (37%) | 49/165 (30%) | 43/81 (53%) | <.0012 |
| 1 year survival with VABS-II score decreased no more than 15 points or improved | 88/301 (29%) | 49/199 (25%) | 39/102 (38%) | 0.0162 |
Denominators reflect subjects with available or eligible data.
1
P-value is based on the Wilcoxon rank-sum test.
2
Fisher’s exact test.
3
Among those with baseline score ≥ 70. If no baseline VABS-II was obtained, a Pediatric Overall Performance Category (POPC) and Pediatric Cerebral Performance Category (PCPC) in the normal or mild disability category met eligibility criteria.